Safe- and green-by-design are pre-market design approaches whereby the objectives of minimizing the use of hazardous chemicals, reducing greenhouse gas emissions, and fostering the reuse and recycling of materials in a circular economy are built into product design.

SUSPHARMA fits the European need for sustainable development in modern industry and will develop during the action greener routes to prepare molecules, such as therapeutics and diagnostics.

The project will thus benefit from an interdisciplinary domain, involving:

• recent advances in biomass conversion for drug synthesis;
• new developments in heterogeneous catalysis;
• cutting-edge flow chemistry technologies (including synthesis and purification);
• automation and machine learning.

With its action, SUSPHARMA aims to address different societal challenges of pharmaceutical synthesis, enabling a reduction of the pollution generated during drug manufacturing.